Publicaciones en colaboración con investigadores/as de University of Amsterdam (36)

2024

  1. A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort

    Schizophrenia Research, Vol. 266, pp. 237-248

  2. PsyCog: A computerised mini battery for assessing cognition in psychosis

    Schizophrenia Research: Cognition, Vol. 37

2023

  1. Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 13, pp. 6150-6160

  2. Development and Validation of Predictive Model for a Diagnosis of First Episode Psychosis Using the Multinational EU-GEI Case-control Study and Modern Statistical Learning Methods

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

  3. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  4. Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis—findings from the EU-GEI study

    Molecular Psychiatry, Vol. 28, Núm. 5, pp. 2095-2106

  5. First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data

    Schizophrenia bulletin, Vol. 49, Núm. 1, pp. 218-227

  6. Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders

    Psychological Medicine, Vol. 53, Núm. 13, pp. 5986-5991

  7. The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study

    Psychological medicine, Vol. 53, Núm. 15, pp. 7418-7427

  8. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications

    Neuroscience and Biobehavioral Reviews, Vol. 149

  9. Tobacco use in first-episode psychosis, a multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7265-7276

  10. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; The EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 8, pp. 3396-3405

2022

  1. Childhood Maltreatment, Educational Attainment, and IQ: Findings from a Multicentric Case-control Study of First-episode Psychosis (EU-GEI)

    Schizophrenia Bulletin, Vol. 48, Núm. 3, pp. 575-589

  2. Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study

    Schizophrenia bulletin, Vol. 48, Núm. 5, pp. 1104-1114

  3. Genetic variants associated with longitudinal changes in brain structure across the lifespan

    Nature neuroscience, Vol. 25, Núm. 4, pp. 421-432

  4. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  5. Migration history and risk of psychosis: Results from the multinational EU-GEI study

    Psychological Medicine, Vol. 52, Núm. 14, pp. 2972-2984

  6. Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study

    Psychological Medicine, Vol. 52, Núm. 15, pp. 3668-3676

2021

  1. Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls

    Psychological Medicine, Vol. 51, Núm. 12, pp. 2074-2082

  2. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study

    Psychological Medicine, Vol. 51, Núm. 8, pp. 1329-1337